Dr. Spencer Nadolsky joins Ethan on the American Glutton Podcast to dive into the revolutionary impact of GLP-1 drugs on obesity and cardiometabolic health, exploring their benefits, risks, and societal implications. From debunking myths about weight loss to discussing emerging treatments like myostatin inhibitors, they tackle the science and real-world applications head-on. The conversation also touches on the future of these medications, their potential to prevent weight gain, and the importance of combining them with lifestyle changes like resistance training.
SHOW HIGHLIGHTS
00:00 - Introduction and Catching Up
00:35 - Obesity as a Choice and GLP-1 Drugs
01:58 - Misuse of GLP-1s and Social Media Hype
05:08 - The Science Behind GLP-1 and Incretin Effect
07:37 - How GLP-1 Drugs Work for Weight Loss
10:00 - Benefits vs. Risks of GLP-1 Drugs
11:57 - Common Side Effects and Nausea Discussion
13:15 - Fatigue and Anhedonia as Side Effects
14:54 - Fat Cell Memory and Weight Regain
17:41 - GLP-1s as a Breakthrough for Obesity
19:33 - Comparing Risks of GLP-1s to Other Drugs
20:24 - Big Pharma and Advisory Boards
23:57 - Importance of Protein and Resistance Training
27:34 - Myostatin Inhibitors and Muscle Growth
31:39 - Timeline for New Drug Approvals
33:31 - Drug Costs and Accessibility
37:51 - Comparing GLP-1 Drugs and Zepbound
39:57 - Glucagon and Triple Agonist Drugs
41:58 - Future of GLP-1s in Preventing Weight Gain
43:43 - Microdosing and Anti-Inflammatory Effects
44:33 - GLP-1s and Type 1 Diabetes Considerations
48:50 - Historical Context and Obesity Trends
52:37 - Moralizing Weight and Pharmaceutical Solutions
54:03 - Closing Thoughts and Future Support
","author_name":"American Glutton"}